Abbott Laboratories
ABT
$87.91
+4.07%
Abbott Laboratories is a diversified global healthcare leader that manufactures and markets a broad portfolio of products, including cardiovascular and diabetes devices, diagnostic equipment, nutritional products, and branded generic pharmaceuticals. The company is a dominant player in the medical devices and diagnostics space, with a distinct competitive identity built on a century-long legacy of innovation, a geographically diversified revenue base, and a strong portfolio of market-leading brands like its continuous glucose monitoring systems. The current investor narrative is dominated by a significant stock price decline following a guidance cut for 2026, which has overshadowed solid quarterly earnings performance and raised concerns about near-term headwinds, even as long-term bulls highlight the company's resilient core businesses, strategic acquisitions, and its impressive 54-year track record of consecutive dividend increases.…
ABT
Abbott Laboratories
$87.91
Related headlines
Investment Opinion: Should I buy ABT Today?
Rating & Thesis: Hold. Abbott Laboratories presents a classic 'value trap' scenario where compelling long-term fundamentals are overshadowed by severe near-term technical and sentiment damage; investors should wait for evidence of a bottom formation before committing new capital. This is consistent with the maintained but cautious analyst bullishness, as the stock needs to stabilize before the implied upside to forward earnings can be realized.
Supporting Evidence: The forward P/E of 13.9x is reasonable for a high-quality healthcare conglomerate and suggests the market has priced in significant pessimism. The company's financial health is impeccable, with $7.4 billion in TTM free cash flow and a debt-to-equity ratio of 0.29. Revenue growth remains positive at 4.4% YoY, and profitability is solid with a 15.5% net margin. However, these strengths are counterbalanced by a trailing P/E of 33.6x, a stock price down 36.7% over the past year, and persistent negative momentum that shows no signs of abating.
Risks & Conditions: The two biggest risks are 1) further earnings guidance cuts invalidating the forward P/E thesis, and 2) a technical breakdown below $82 support triggering another leg down. This Hold rating would upgrade to a Buy if the stock establishes a firm base above $82 and shows sustained positive relative strength for at least a month, or if forward earnings estimates are revised upwards. It would downgrade to a Sell if the stock breaks below $81.97 on high volume or if quarterly revenue growth turns negative. The stock is currently fairly valued on a forward basis but remains overvalued on trailing metrics, with the market expecting a sharp earnings recovery to bridge the gap.
Sign up to view all
ABT 12-Month Price Forecast
The outlook is bifurcated between a compelling valuation on forward earnings and a deeply damaged price chart. The base case of stabilization and gradual recovery is most probable (50%), as the company's financial fortress provides a floor, but regaining investor trust will take time. The bull case (30%) depends on a swift reversal of sentiment, which is possible given the oversold extreme. The bear case (20%) cannot be dismissed due to the clear technical breakdown and reliance on future earnings delivery. The stance would upgrade to bullish on a confirmed technical reversal above $110, or turn bearish on a sustained break below $81.97.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Abbott Laboratories's 12-month outlook, with a consensus price target around $114.28 and implied upside of +30.0% versus the current price.
Average Target
$114.28
9 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
9
covering this stock
Price Range
$70 - $114
Analyst target range
Abbott Laboratories is covered by 9 analysts, and the institutional sentiment remains predominantly bullish, as evidenced by recent actions from firms like Citigroup, Barclays, and RBC Capital maintaining Buy or Outperform ratings. While a precise consensus recommendation and average target price are not provided in the data, the pattern of recent ratings indicates strong analyst conviction in the long-term story despite near-term headwinds. The range of analyst expectations can be inferred from the provided EPS and revenue estimates. The consensus EPS estimate for the coming year is $8.36, with a low estimate of $8.01 and a high of $8.43, representing a very tight range of just 5.2%. Similarly, revenue estimates average $68.25 billion, with a range from $66.09 billion to $68.71 billion. This narrow target spread signals high analyst conviction and agreement on the company's fundamental outlook, reducing the uncertainty typically associated with wide dispersions. The recent guidance cut has likely anchored estimates toward the lower end, but the maintained bullish ratings suggest analysts view the sell-off as an overreaction creating a buying opportunity.
Bulls vs Bears: ABT Investment Factors
The evidence presents a stark clash between deteriorating price momentum and deeply oversold conditions against a backdrop of fundamentally sound operations. The bear side currently has stronger near-term evidence, driven by the severe technical breakdown and the market's punitive reaction to the guidance cut. However, the bull case is supported by compelling valuation metrics on a forward basis and exceptional financial health. The single most important tension in the investment debate is whether the company's solid fundamentals and analyst confidence will soon arrest the negative momentum, or if the technical and sentiment damage will persist, forcing a further derating of the stock. The resolution hinges on Abbott's ability to demonstrate that the 2026 guidance cut was a one-time reset rather than the start of a prolonged downturn.
Bullish
- Strong Fundamentals Undersold: The company maintains robust profitability with a Q4 net margin of 15.5% and generates massive free cash flow of $7.4 billion TTM, funding its dividend and growth. The forward P/E of 13.9x, based on $8.36 EPS estimates, is at the low end of its historical range, suggesting significant pessimism is priced in.
- Extreme Oversold Technicals: The stock is down 36.7% over the past year and trades just 2.2% above its 52-week low of $81.97, indicating deep oversold conditions. This severe underperformance versus the S&P 500 by over 61 percentage points suggests negative sentiment is overextended, creating potential for a sharp mean-reversion bounce.
- Analyst Conviction Remains High: Despite the sell-off, analysts maintain bullish ratings, and forward EPS estimates show a tight range of just 5.2% between low and high targets. This high conviction, with an average EPS estimate of $8.36, signals confidence in the company's ability to navigate near-term headwinds.
- Rock-Solid Financial Health: Abbott boasts a fortress balance sheet with a low debt-to-equity ratio of 0.29 and a strong current ratio of 1.58. This financial strength supports its 54-year track record of consecutive dividend increases and provides a buffer against economic uncertainty.
Bearish
- Severe Negative Momentum & Guidance Cut: The stock is down 25.0% over the past three months and 16.8% over the past month, with accelerating downward pressure. This was triggered by a 2026 profit guidance cut that overshadowed a solid Q1 earnings beat, signaling persistent investor concern over near-term headwinds.
- Elevated Trailing Valuation: The trailing P/E of 33.6x is significantly elevated, reflecting compressed earnings and a premium valuation that may not be justified if growth decelerates further. The price-to-sales ratio of 4.94 also indicates the market is valuing revenue at a premium despite the recent downturn.
- High Reliance on Forward Earnings Recovery: The investment thesis hinges on a substantial earnings recovery to meet the forward EPS of $8.36, which would represent a dramatic increase from the most recent quarterly EPS of $1.02. Any further guidance cuts or execution missteps would invalidate the forward P/E argument and lead to multiple compression.
- Persistent Underperformance vs. Market: The stock's relative strength versus the S&P 500 is a staggering -22.4 over one month and -61.8 over one year, indicating a severe and sustained loss of investor favor. This trend divergence suggests company-specific issues are outweighing its low beta of 0.65, which typically provides market insulation.
ABT Technical Analysis
The prevailing price trend for Abbott Laboratories is a pronounced and sustained downtrend, with the stock down 36.66% over the past year and trading near the bottom of its 52-week range. With a current price of $84.47, the stock is trading at just 2.2% above its 52-week low of $81.97, positioning it in deep oversold territory which may represent a value opportunity but also signals significant negative momentum and investor pessimism. Recent short-term momentum shows no signs of reversal, with the stock down 16.83% over the past month and 25.04% over the past three months, indicating accelerating downward pressure that is diverging sharply from the broader market's positive performance, as evidenced by a staggering -22.43 relative strength reading versus the S&P 500 over the same period. Key technical support is clearly defined at the 52-week low of $81.97, while resistance is far above at the 52-week high of $139.06. A decisive breakdown below the $82 support level would signal a continuation of the bearish trend and potentially trigger further selling, whereas a rebound from this level could indicate a technical bottom is forming. The stock's beta of 0.647 indicates it is approximately 35% less volatile than the broader market, which is typical for a large-cap healthcare company but has not insulated it from severe price declines, as evidenced by a maximum drawdown of -40.21% over the provided period. The stock's extreme positioning is further highlighted by its performance relative to the market; while the S&P 500 is up 25.19% over the past year, Abbott has underperformed by over 61 percentage points. This severe underperformance, combined with the stock trading just pennies above its 52-week low, suggests the market has priced in significant negative news, and any positive catalyst could lead to a sharp mean-reversion bounce, though the persistent negative momentum warns that the trend remains firmly down.
Beta
0.65
0.65x market volatility
Max Drawdown
-40.2%
Largest decline past year
52-Week Range
$82-$139
Price range past year
Annual Return
-34.8%
Cumulative gain past year
| Period | ABT Return | S&P 500 |
|---|---|---|
| 1m | -9.2% | +4.0% |
| 3m | -21.7% | +8.2% |
| 6m | -30.3% | +11.5% |
| 1y | -34.8% | +24.3% |
| ytd | -29.2% | +8.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ABT Fundamental Analysis
Abbott's revenue trajectory shows modest but consistent growth, with Q4 2025 revenue of $11.46 billion representing a 4.42% year-over-year increase. The multi-quarter trend reveals steady sequential growth from $10.36 billion in Q1 to the Q4 figure, indicating a stable, albeit not explosive, growth profile. Revenue segment data shows Medical Devices as the dominant driver, contributing $5.68 billion, followed by Nutritional Products at $1.94 billion and Established Pharmaceuticals at $1.38 billion, confirming the company's core strength in high-margin device markets. The company remains solidly profitable, with Q4 2025 net income of $1.78 billion and a net margin of 15.5%. Profitability metrics are healthy, with a gross margin of 57.05% and an operating margin of 19.64% for the quarter, reflecting the premium nature of its medical device portfolio. Margins have shown stability, with the quarterly gross margin hovering between 52.6% and 57.1% over the past year, demonstrating strong pricing power and cost management despite potential inflationary pressures. Abbott's balance sheet and cash flow position are exceptionally strong, underpinning its financial health. The company boasts a robust current ratio of 1.58 and a conservative debt-to-equity ratio of 0.29, indicating ample liquidity and a low reliance on debt financing. Most impressively, Abbott generated $7.40 billion in trailing twelve-month free cash flow, providing massive internal funding for its growth initiatives, dividend payments (with a 63% payout ratio), and share repurchases. The return on equity of 12.5% is respectable for a large-cap healthcare company and is supported by this powerful cash generation engine.
Quarterly Revenue
$11.5B
2025-12
Revenue YoY Growth
+0.04%
YoY Comparison
Gross Margin
+0.57%
Latest Quarter
Free Cash Flow
$7.4B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ABT Overvalued?
Given Abbott's positive net income, the primary valuation metric is the Price-to-Earnings (PE) ratio. The stock currently trades at a trailing PE of 33.55x, which is significantly higher than its forward PE of 13.93x. This wide gap implies the market expects a substantial recovery in earnings, as the forward multiple is based on consensus EPS estimates of $8.36 for the coming year, compared to the most recent quarterly EPS of $1.02. Compared to sector averages, Abbott's valuation presents a mixed picture. Its trailing PE of 33.55x is elevated, but its forward PE of 13.93x appears more reasonable for a high-quality healthcare conglomerate. The price-to-sales ratio of 4.94 and EV-to-Sales of 3.89 further suggest the market is valuing the company's revenue stream at a premium, which may be justified by its industry-leading margins and diversified portfolio, though the recent guidance cut has pressured these multiples. Historically, Abbott's current trailing PE of 33.55x sits above its own recent range, as seen in historical data where it fluctuated between 5.31x (an anomaly due to a one-time tax benefit in Q4 2024) and 46.17x over the past several years. However, the more relevant forward PE of 13.93x is near the lower end of its historical spectrum, suggesting the market has already discounted significant pessimism regarding future earnings growth. This historical context indicates that if the company can meet or exceed its lowered guidance, there is room for multiple expansion.
PE
33.6x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 5x~46x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
19.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Abbott's primary financial risk is not leverage or liquidity—its balance sheet is exceptionally strong—but rather earnings volatility and valuation dependency. The trailing P/E of 33.6x is high and relies on a significant earnings rebound to justify the forward multiple of 13.9x. A failure to achieve the consensus EPS of $8.36 would trigger multiple compression. Furthermore, while diversified, the company derives significant revenue from its Medical Devices segment ($5.68B in Q4), making it susceptible to regulatory delays, reimbursement changes, or competitive product launches in this core market.
Market & Competitive Risks: The stock faces acute valuation compression risk, as its current price-to-sales of 4.94 and EV/Sales of 3.89 represent a premium that is being challenged. The stock's beta of 0.647 has not protected it from a 40.2% maximum drawdown, indicating company-specific risks are dominating. Competitive and regulatory pressures in key areas like diabetes care (continuous glucose monitors) and diagnostics could pressure growth and margins. The recent news of a guidance cut has cemented a negative narrative that may take multiple quarters of outperformance to reverse.
Worst-Case Scenario: The worst-case scenario involves a continuation of the current negative momentum, culminating in a breakdown below the key $81.97 support level. This could be triggered by another guidance reduction, a major product setback, or a broader sector rotation out of healthcare. In this adverse scenario, the stock could re-test its 52-week low and potentially fall further, towards a level implied by a high-single-digit P/E on lowered earnings, representing a downside of 20-30% from the current price. The realistic downside to the 52-week low is approximately -3%, but a breach could see losses extend to the -15% to -20% range, aligning with the stock's demonstrated maximum drawdown potential.
FAQ
The key risks are, in order of severity: 1) Execution & Guidance Risk: Failure to meet the forward EPS target of $8.36, which the entire valuation hinges upon, could trigger further multiple compression. 2) Technical & Sentiment Risk: The stock is in a powerful downtrend and a break below $82 support could lead to another 15-20% decline, as seen in its -40.2% max drawdown. 3) Competitive/Market Risk: Pressure in core markets like diabetes devices or nutrition could slow growth below the current 4.4% rate. 4) Macro Risk: While its beta is low at 0.65, a recession could impact elective procedure volumes and consumer spending on nutritional products.
The 12-month forecast is a wide range reflecting high uncertainty. The base case (50% probability) sees the stock stabilizing between $95 and $110 as it meets its $8.36 EPS guidance but struggles with multiple expansion. The bull case (30% probability) projects a rally to $125-$139 on a sentiment reversal and earnings beat. The bear case (20% probability) warns of a drop to $75-$85 on further guidance cuts and technical breakdown. The most likely outcome is the base case, predicated on the assumption that Abbott's fundamental strength eventually halts the decline, but the damaged chart prevents a rapid V-shaped recovery.
ABT's valuation is a tale of two metrics, making it fairly valued with a skew towards undervaluation on a forward-looking basis. The trailing P/E of 33.6x is elevated and suggests overvaluation based on recent earnings. However, the more relevant forward P/E of 13.9x is reasonable and sits at the low end of its historical range, implying the market has discounted significant bad news. Compared to sector peers, this forward multiple is not demanding for a company with its margins and cash flow. The valuation implies the market expects a strong earnings recovery to $8.36 EPS; if achieved, the stock is undervalued. If not, it remains overvalued.
ABT is a complex buy at current levels. For long-term, patient investors, the forward P/E of 13.9x and the 54-year dividend growth history present a compelling case, especially with the stock trading near its 52-week low. However, for most investors, it is not a good buy today due to the severe negative momentum and lack of a clear technical bottom; the stock could easily fall further before recovering. It is a good buy for those with a multi-year horizon who believe in the company's fundamentals and are willing to average down if necessary, but a poor choice for short-term traders or those sensitive to volatility.
ABT is unequivocally suitable only for long-term investment at this juncture. The severe negative momentum and lack of a defined bottom make it a poor candidate for short-term trading. Its low beta of 0.65, consistent dividend growth, and strong cash flow generation are hallmarks of a long-term holding. Investors should be prepared to hold for a minimum of 3-5 years to allow the fundamental story to overcome the current technical and sentiment overhang. The stock's volatility during this drawdown period is better weathered by long-term investors focused on the underlying business, not the daily price action.
